Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma

Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma

Item
http://www.wikidata.org/entity/Q33754122
Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter StudyEfficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysisAssessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinomaTargeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus.Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma.Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model.The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective studyComparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.
P2860

Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma

Item
http://www.wikidata.org/entity/Q33754122
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Critical appraisal of sorafeni ...... ents with renal cell carcinoma
@ast
Critical appraisal of sorafeni ...... ents with renal cell carcinoma
@en
type
label
Critical appraisal of sorafeni ...... ents with renal cell carcinoma
@ast
Critical appraisal of sorafeni ...... ents with renal cell carcinoma
@en
prefLabel
Critical appraisal of sorafeni ...... ents with renal cell carcinoma
@ast
Critical appraisal of sorafeni ...... ents with renal cell carcinoma
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P478
P577
P698
P932
P356
P1433
P1476
Critical appraisal of sorafeni ...... ents with renal cell carcinoma
@en
P2093
P2860
P304
P31
P356
P407
P478
P577
P698
P932